

INJECTION DEVICES

Bespak by Recipharm delivers market leading design, development, and manufacturing services for drug delivery devices to the global pharmaceutical market. Our portfolio includes inhalers, nasal technologies, and auto-injectors as well as development and manufacturing services. We have developed a range of customisable solutions for the injectable delivery of high viscosity drugs.



MORE ABOUT OUR PORTFOLIO



SYRINA® AS AUTO-INJECTOR

- ▶ Our most advanced auto-injector
- ▶ Featuring automatic needle insertion and audible end of dose indication
- ▶ For use with 2.25 ml and 1ml pre-filled syringes



VISCALA® AUTO-INJECTOR

- ▶ Designed to deliver ultra-high viscosity formulations through thin needles



SYRINA® MICRO ASSISTED SYRINGE

- ▶ Ideal solution for replacing conventional plunger rods to deliver viscous drug products through thin needles
- ▶ Perfect for blinded studies to conceal differences in drugs/placebos

VAPOURSOFT® TECHNOLOGY

Our VapourSoft® technology using liquefied gas is used in our Syrina® and Viscalà® range of injectable devices to allow for greater flexibility in device designs when compared to conventional spring-based auto-injectors.



ADVANTAGES INCLUDED:

- ▶ A flexible energy source that enables the propellant to be altered within a single container format to tailor performance according to drug viscosity, needle, fill volume and drug delivery time
- ▶ The ability to deliver high viscosity drugs with ease
- ▶ Soft start delivery mechanism that reduces impact, making it ideal for glass primary containers
- ▶ Constant pressure profile which supports lower peak forces than conventional spring-based auto-injectors



About Bepak by Recipharm: Bepak by Recipharm delivers market leading design, development and manufacture of drug delivery devices to the global pharmaceutical market. This includes inhaler, nasal technologies and auto-injectors as well as development and manufacturing services. Recipharm is at the leading edge of drug delivery device innovation. Driven by customer and patient demand, our innovations have the potential to create new treatments and opportunities across the globe as well as accelerating routes to market.